OncoMatch/Clinical Trials/NCT06423326
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Official title: A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Is NCT06423326 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Cisplatin and Gemcitabine for borderline resectable pancreatic ductal adenocarcinoma.
Treatment: Cisplatin · Gemcitabine · Nab-paclitaxel — This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy is more feasible and could improve outcomes compared to patients receiving surgery first. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel, an antimicrotubule agent that stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel may have fewer side effects and work better than other forms of paclitaxel. Gemcitabine, cisplatin and nab-paclitaxel may be an effective neoadjuvant treatment option for patients with resectable or borderline resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage I, II, III (other)
Official conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage I Pancreatic Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500 cells/ul; Platelet count ≥ 100,000 cells/ul; Hemoglobin ≥ 9 g/dL
Kidney function
Creatinine ≤ 1.5 x ULN
Liver function
Serum total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 x ULN; Albumin ≥ 3 g/dl
Adequate Bone marrow reserves as evidenced by: Absolute neutrophil count (ANC) ≥ 1,500 cells/ul; Platelet count ≥ 100,000 cells/ul; Hemoglobin ≥ 9 g/dL. Adequate hepatic function as evidence by: Serum total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 x ULN; Albumin ≥ 3 g/dl. Adequate renal function as evidenced by Creatinine ≤ 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Lombardi Comprehensive Cancer Center, Georgetown University · Washington D.C., District of Columbia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06423326 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages